Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A re-analysis of a series of studies of vaginally-administered progesterone versus intramuscular progesterone injections has demonstrated that, when evaluating optimal dosing, clinical results are comparable for early pregnancy support in assisted reproductive technology cycles, according to a study supported by a grant from Columbia Laboratories, Inc.
Subscribe to our email newsletter
The re-analysis demonstrates that vaginal progesterone is associated with a significantly lower rate of miscarriage than IM progesterone. The data was presented by Dr Paul Zarutskie, Zarutskie Fertility and Endocrine Institute, Laguna Niguel, CA.
The original analysis of 10 studies (a meta-analysis) included research with different vaginal progesterone preparations, including oil capsules, vaginal cream and Crinone 8% (a bioadhesive progesterone gel), using a wide range of doses. The re-analysis included 8 studies; 6 studies of Crinone 8% once daily and 2 studies of 200mg of progesterone in oil capsules, administered 3 times daily, versus IM progesterone.
Dr Zarutskie, said: “Our objective was to analyze the existing data and new data published in 2006, but without including studies that used suboptimal doses of progesterone, to get an unbiased, true comparison. Our re-analysis shows no difference in the clinical pregnancy rate between IM and vaginal progesterone administration for luteal phase support in in vitro fertilization, when using optimal dosing of vaginally administered progesterone. Data also show a significantly reduced rate of miscarriage with Crinone 8% and progesterone in oil capsules over IM progesterone dosing.”